Engineering hydrophobicity and manufacturability for optimized biparatopic antibody–drug conjugates targeting c-MET

References

• Markham A. Tepotinib: First Approval. Drugs. 2020;80:829–13. doi:10.1007/s40265-020-01317-9.
   PubMed Web of Science ®Google Scholar
• Awad MM, Liu S, II R, KC A, Dilly J, VW Z, ML J, RS H, Patil T, GJ R. et al. Acquired resistance to KRASG12C inhibition in cancer. N Engl J Med. 2021;384(25):2382–93. doi:10.1056/NEJMoa2105281.
   PubMed Web of Science ®Google Scholar
• Camidge DR, Davies KD. MET copy number as a secondary driver of epidermal growth factor receptor tyrosine kinase inhibitor resistance in EGFR -mutant non–small-Cell lung cancer. JCO. 2019;37(11):855–57. doi:10.1200/JCO.19.00033.
   PubMed Web of Science ®Google Scholar
• Chmielecki J, Gray JE, Cheng Y, Ohe Y, Imamura F, Cho BC, Lin M-C, Majem M, Shah R, Rukazenkov Y. et al. Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer. Nat Commun. 2023;14(1):1070. doi:10.1038/s41467-023-35961-y.
   PubMed Web of Science ®Google Scholar
• Yang J, Zhou P, Yu M. Zhang YCase report: high-level MET amplification as a resistance mechanism of ROS1-tyrosine kinase inhibitors in ROS1-rearranged non-smallcell lung cancer.Frontiers In Oncology [Internet]. 2021; 2023 Jul 5] 11: doi:10.3389/fonc.2021.645224.
   Google Scholar
• Rong S, Segal S, Anver M, Resau JH, Vande Woude GF. Invasiveness and metastasis of NIH 3T3 cells induced by met-hepatocyte growth factor/scatter factor autocrine stimulation. Proc Natl Acad Sci U S A. 1994 May 24;91(11):4731–35. doi:10.1073/pnas.91.11.4731.
   Google Scholar
• Lai AZ, Cory S, Zhao H, Gigoux M, Monast A, Guiot M-C, Huang S, Tofigh A, Thompson C, Naujokas M. et al. Dynamic reprogramming of signaling upon met inhibition reveals a mechanism of drug resistance in gastric cancer. Sci Signal. 2014;7(322):ra38. doi:10.1126/scisignal.2004839.
   PubMed Web of Science ®Google Scholar
• Gherardi E, Birchmeier W, Birchmeier C, Vande Woude G. Targeting MET in cancer: rationale and progress. Nat Rev Cancer. 2012;12(2):89–103. doi:10.1038/nrc3205.
   PubMed Web of Science ®Google Scholar
• KK-W T, Leung K-S, Cho W-S. MET-Targeting anticancer drugs—De novo design and identification by drug repurposing. DDC. 2023;2(3):591–623. doi:10.3390/ddc2030031.
   Google Scholar
• De Mello RA, Neves NM, Amaral GA, Lippo EG, Castelo-Branco P, Pozza DH, Tajima CC, Antoniou G. The role of MET inhibitor therapies in the treatment of advanced non-small cell lung cancer. J Clin Med. 2020;9(6):1918. doi:10.3390/jcm9061918.
   PubMed Web of Science ®Google Scholar
• Garon EB, Brodrick P. Targeted therapy approaches for MET abnormalities in non-small cell lung cancer. Drugs. 2021;81(5):547–54. doi:10.1007/s40265-021-01477-2.
   PubMed Web of Science ®Google Scholar
• Huo X, Shen G, Liu Z, Liang Y, Li J, Zhao F, Ren D, Zhao J. Addition of immunotherapy to chemotherapy for metastatic triple-negative breast cancer: a systematic review and meta-analysis of randomized clinical trials. Crit Rev Oncol Hematol. 2021;168:103530. doi:10.1016/j.critrevonc.2021.103530.
   PubMed Web of Science ®Google Scholar
• Shah V, McNatty A, Simpson L, Ofori H, Raheem F. Amivantamab-vmjw: a novel treatment for patients with NSCLC harboring EGFR Exon 20 insertion mutation after progression on platinum-based chemotherapy. Biomedicines. 2023;11:950. doi:10.3390/biomedicines11030950.
   PubMed Web of Science ®Google Scholar
• Casaletto JB, Geddie ML, Abu-Yousif AO, Masson K, Fulgham A, Boudot A, Maiwald T, Kearns JD, Kohli N, Su S. et al. MM-131, a bispecific anti-Met/EpCAM mAb, inhibits HGF-dependent and HGF-independent met signaling through concurrent binding to EpCAM. Proc Natl Acad Sci U S A. 2019;116(15):7533–42. doi:10.1073/pnas.1819085116.
   PubMed Web of Science ®Google Scholar
• Lee B-S, Kang S, Kim K-A, Song Y-J, Cheong KH, Cha H-Y, Kim C-H. Met degradation by SAIT301, a met monoclonal antibody, reduces the invasion and migration of nasopharyngeal cancer cells via inhibition of EGR-1 expression. Cell Death Disease. 2014;5(4):e1159. doi:10.1038/cddis.2014.119.
   PubMedGoogle Scholar
• Liu L, Zeng W, Wortinger MA, Yan SB, Cornwell P, Peek VL, Stephens JR, Tetreault JW, Xia J, Manro JR. et al. LY2875358, a neutralizing and internalizing anti-MET bivalent antibody, inhibits HGF-dependent and HGF-independent MET activation and tumor growth. Clin Cancer Res. 2014;20(23):6059–70. doi:10.1158/1078-0432.CCR-14-0543.
   PubMed Web of Science ®Google Scholar
• Su Z, Han Y, Sun Q, Wang X, Xu T, Xie W, Huang X. Anti-MET VHH pool overcomes MET-Targeted cancer therapeutic resistance. Mol Cancer Ther. 2019;18(1):100–11. doi:10.1158/1535-7163.MCT-18-0351.
   PubMed Web of Science ®Google Scholar
• Benedetti F, Stadlbauer K, Stadlmayr G, Rüker F, Wozniak-Knopp G. A tetravalent biparatopic antibody causes strong HER2 internalization and inhibits cellular proliferation. Life (Basel). 2021;11(11):1157. doi:10.3390/life11111157.
   PubMed Web of Science ®Google Scholar
• DaSilva JO, Yang K, Perez Bay AE, Andreev J, Ngoi P, Pyles E, Franklin MC, Dudgeon D, Rafique A, Dore A. et al. A biparatopic antibody that modulates MET trafficking exhibits enhanced efficacy compared with parental antibodies in MET-Driven tumor models. Clin Cancer Res. 2020;26(6):1408–19. doi:10.1158/1078-0432.CCR-19-2428.
   PubMed Web of Science ®Google Scholar
• Paul D, Stern O, Vallis Y, Dhillon J, Buchanan A, McMahon H. Cell surface protein aggregation triggers endocytosis to maintain plasma membrane proteostasis. Nat Commun. 2023;14(1):947. doi:10.1038/s41467-023-36496-y.
   PubMed Web of Science ®Google Scholar
• DaSilva JO, Yang K, Surriga O, Nittoli T, Kunz A, Franklin MC, Delfino FJ, Mao S, Zhao F, Giurleo JT. et al. A biparatopic antibody–drug conjugate to treat MET-Expressing cancers, including those that are unresponsive to MET pathway blockade. Mol Cancer Ther. 2021;20(10):1966–76. doi:10.1158/1535-7163.MCT-21-0009.
   PubMed Web of Science ®Google Scholar
• Li JY, Perry SR, Muniz-Medina V, Wang X, Wetzel LK, Rebelatto MC, Hinrichs MJM, Bezabeh BZ, Fleming RL, Dimasi N. et al. A biparatopic HER2-targeting antibody-drug conjugate induces tumor regression in primary models refractory to or ineligible for HER2-targeted therapy. Cancer Cell. 2016;29(1):117–29. doi:10.1016/j.ccell.2015.12.008.
   PubMed Web of Science ®Google Scholar
• Oh SY, Lee YW, Lee EJ, Kim JH, Park Y, Heo SG, Yu MR, Hong MH, DaSilva J, Daly C. et al. Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC. Clin Cancer Res. 2023;29(1):221–32. doi:10.1158/1078-0432.CCR-22-2180.
   PubMed Web of Science ®Google Scholar
• Sellmann C, Doerner A, Knuehl C, Rasche N, Sood V, Krah S, Rhiel L, Messemer A, Wesolowski J, Schuette M. et al. Balancing selectivity and efficacy of bispecific Epidermal Growth Factor Receptor (EGFR) × c-MET antibodies and antibody-drug conjugates. J Biol Chem. 2016;291(48):25106–19. doi:10.1074/jbc.M116.753491.
   PubMed Web of Science ®Google Scholar
• Leung D, Wurst J, Liu T, Martinez R, Datta-Mannan A, Feng Y. Antibody conjugates-recent advances and future innovations. Antibodies. 2020;9(1):2. doi:10.3390/antib9010002.
   Web of Science ®Google Scholar
• Mckertish CM, Kayser V. Advances and limitations of antibody drug conjugates for cancer. Biomedicines. 2021;9(8):872. doi:10.3390/biomedicines9080872.
   PubMed Web of Science ®Google Scholar
• Tsuchikama K, An Z. Antibody-drug conjugates: recent advances in conjugation and linker chemistries. Protein Cell. 2018;9(1):33–46. doi:10.1007/s13238-016-0323-0.
   PubMed Web of Science ®Google Scholar
• Buecheler JW, Winzer M, Weber C, Gieseler H. Alteration of physicochemical properties for antibody-drug conjugates and their impact on stability. J Pharm Sci. 2020;109(1):161–68. doi:10.1016/j.xphs.2019.08.006.
   PubMed Web of Science ®Google Scholar
• Lyon RP, Bovee TD, Doronina SO, Burke PJ, Hunter JH, Neff-LaFord HD, Jonas M, Anderson ME, Setter JR, Senter PD. Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index. Nat Biotechnol. 2015;33(7):733–35. doi:10.1038/nbt.3212.
   PubMed Web of Science ®Google Scholar
• Wagh A, Song H, Zeng M, Tao L, Das TK. Challenges and new frontiers in analytical characterization of antibody-drug conjugates. MAbs. 2018;10(2):222–43. doi:10.1080/19420862.2017.1412025.
   PubMed Web of Science ®Google Scholar
• Davis JH, Aperlo C, Li Y, Kurosawa E, Lan Y, Lo K-M, Huston JS. Seedbodies: fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies†. Protein Engineering, Design And Selection. 2010;23(4):195–202. doi:10.1093/protein/gzp094.
   PubMed Web of Science ®Google Scholar
• Labrijn AF, Meesters JI, De Goeij BECG, Van Den Bremer ETJ, Neijssen J, Van Kampen MD, Strumane K, Verploegen S, Kundu A, Gramer MJ. et al. Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange. Proc Natl Acad Sci U S A. 2013;110(13):5145–50. doi:10.1073/pnas.1220145110.
   PubMed Web of Science ®Google Scholar
• Evers A, Malhotra S, Bolick W-G, Najafian A, Borisovska M, Warszawski S, Fomekong Nanfack Y, Kuhn D, Rippmann F, Crespo A. et al. SUMO. Silico Sequence Assessment Using Multiple Optimization Parameters Methods Mol Biol. 2023;2681:383–98.
   Google Scholar
• Schaefer W, Regula JT, Bähner M, Schanzer J, Croasdale R, Dürr H, Gassner C, Georges G, Kettenberger H, Imhof-Jung S. et al. Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies. Proceedings of the National Academy of Sciences 2011; 108:11187–92.
   Google Scholar
• Liu Y, Caffry I, Wu J, Geng SB, Jain T, Sun T, Reid F, Cao Y, Estep P, Yu Y. et al. High-throughput screening for developability during early-stage antibody discovery using self-interaction nanoparticle spectroscopy. MAbs. 2014;6(2):483–92. doi:10.4161/mabs.27431.
   PubMed Web of Science ®Google Scholar
• Jain T, Sun T, Durand S, Hall A, Houston NR, Nett JH, Sharkey B, Bobrowicz B, Caffry I, Yu Y. et al. Biophysical properties of the clinical-stage antibody landscape. Proc Natl Acad Sci U S A. 2017;114(5):944–49. doi:10.1073/pnas.1616408114.
   PubMed Web of Science ®Google Scholar
• Xu Y, Roach W, Sun T, Jain T, Prinz B, Yu T-Y, Torrey J, Thomas J, Bobrowicz P, Vásquez M. et al. Addressing polyspecificity of antibodies selected from an in vitro yeast presentation system: a FACS-based, high-throughput selection and analytical tool. Protein Eng Des Sel. 2013;26(10):663–70. doi:10.1093/protein/gzt047.
   PubMed Web of Science ®Google Scholar
• WO2023170240A1.
   Google Scholar
• YY S. Amivantamab: First Approval. Drugs. 2021;81(11):1349–53. doi:10.1007/s40265-021-01561-7.
   PubMed Web of Science ®Google Scholar
• Cotton AD, Nguyen DP, Gramespacher JA, Seiple IB, Wells JA. Development of antibody-based PROTACs for the Degradation of the Cell-Surface Immune Checkpoint Protein PD-L1. J Am Chem Soc. 2021;143(2):593–98. doi:10.1021/jacs.0c10008.
   PubMed Web of Science ®Google Scholar
• Zhang H, Han Y, Yang Y, Lin F, Li K, Kong L, Liu H, Dang Y, Lin J, Chen PR. Covalently engineered nanobody chimeras for targeted membrane protein degradation. J Am Chem Soc. 2021;143(40):16377–82. doi:10.1021/jacs.1c08521.
   PubMed Web of Science ®Google Scholar
• Ahn G, Banik SM, Bertozzi CR. Degradation from the outside in: targeting extracellular and membrane proteins for degradation through the endolysosomal pathway. Cell Chem Biol. 2021;28(7):1072–80. doi:10.1016/j.chembiol.2021.02.024.
   PubMed Web of Science ®Google Scholar
• Lin J, Jin J, Shen Y, Zhang L, Gong G, Bian H, Chen H, Nagle DG, Wu Y, Zhang W. et al. Emerging protein degradation strategies: expanding the scope to extracellular and membrane proteins. Theranostics. 2021;11(17):8337–49. doi:10.7150/thno.62686.
   PubMed Web of Science ®Google Scholar
• Kelton C, Wesolowski JS, Soloviev M, Schweickhardt R, Fischer D, Kurosawa E, McKenna SD, Gross AW. Anti-EGFR biparatopic-SEED antibody has enhanced combination-activity in a single molecule. Arch Biochem Biophys. 2012;526(2):219–25. doi:10.1016/j.abb.2012.03.005.
   PubMed Web of Science ®Google Scholar
• Lewis SM, Wu X, Pustilnik A, Sereno A, Huang F, Rick HL, Guntas G, Leaver-Fay A, Smith EM, Ho C. et al. Generation of bispecific IgG antibodies by structure-based design of an orthogonal fab interface. Nat Biotechnol. 2014;32(2):191–98. doi:10.1038/nbt.2797.
   PubMed Web of Science ®Google Scholar
• Reilly RM, Ji C, Matuszak RP, Anderson MG, Tucker L, Klunder N, Lazo AL, Boghaert ER, Pysz MA, D’Souza A. et al. Abstract 6311: ABBV-400: An ADC delivering a novel topoisomerase 1 inhibitor to c-Met-positive solid tumors. Cancer Res. 2023;83(7_Supplement):6311. doi:10.1158/1538-7445.AM2023-6311.
   Web of Science ®Google Scholar
• Bhatta P, Whale KD, Sawtell AK, Thompson CL, Rapecki SE, Cook DA, Twomey BM, Mennecozzi M, Starkie LE, Barry EMC. et al. Bispecific antibody target pair discovery by high-throughput phenotypic screening using in vitro combinatorial fab libraries. MAbs. 2021;13(1):1859049. doi:10.1080/19420862.2020.1859049.
   PubMed Web of Science ®Google Scholar
• Dengl S, Mayer K, Bormann F, Duerr H, Hoffmann E, Nussbaum B, Tischler M, Wagner M, Kuglstatter A, Leibrock L. et al. Format chain exchange (FORCE) for high-throughput generation of bispecific antibodies in combinatorial binder-format matrices. Nat Commun. 2020;11(1):4974. doi:10.1038/s41467-020-18477-7.
   PubMed Web of Science ®Google Scholar
• Apaja PM, Lukacs GL. Protein homeostasis at the plasma membrane. Physiology. 2014;29(4):265–77. doi:10.1152/physiol.00058.2013.
   PubMed Web of Science ®Google Scholar
• Dyson MR, Masters E, Pazeraitis D, Perera RL, Syrjanen JL, Surade S, Thorsteinson N, Parthiban K, Jones PC, Sattar M. et al. Beyond affinity: selection of antibody variants with optimal biophysical properties and reduced immunogenicity from mammalian display libraries. MAbs. 2020;12(1):1829335. doi:10.1080/19420862.2020.1829335.
   PubMed Web of Science ®Google Scholar
• Huhtinen O, Salbo R, Lamminmäki U, Prince S. Selection of biophysically favorable antibody variants using a modified flp-in CHO mammalian display platform. Front Bioeng Biotechnol. 2023;11:1170081. doi:10.3389/fbioe.2023.1170081.
   PubMed Web of Science ®Google Scholar
• Makowski EK, Chen H, Lambert M, Bennett EM, Eschmann NS, Zhang Y, Zupancic JM, Desai AA, Smith MD, Lou W. et al. Reduction of therapeutic antibody self-association using yeast-display selections and machine learning. MAbs. 2022;14(1):2146629. doi:10.1080/19420862.2022.2146629.
   PubMed Web of Science ®Google Scholar
• Gérard A, Woolfe A, Mottet G, Reichen M, Castrillon C, Menrath V, Ellouze S, Poitou A, Doineau R, Briseno-Roa L. et al. High-throughput single-cell activity-based screening and sequencing of antibodies using droplet microfluidics. Nat Biotechnol. 2020;38(6):715–21. doi:10.1038/s41587-020-0466-7.
   PubMed Web of Science ®Google Scholar
• Mason DM, Friedensohn S, Weber CR, Jordi C, Wagner B, Meng SM, Ehling RA, Bonati L, Dahinden J, Gainza P. et al. Optimization of therapeutic antibodies by predicting antigen specificity from antibody sequence via deep learning. Nat Biomed Eng. 2021;5(6):600–12. doi:10.1038/s41551-021-00699-9.
   PubMed Web of Science ®Google Scholar
• Datta-Mannan A, Choi H, Jin Z, Lu J, Liu L, Stokell D, Murphy A, Dunn K, Martinez M, Feng Y. Reducing target binding affinity improves the Therapeutic Index of Anti-MET Antibody Drug Conjugate in tumor Bearing Animals [internet]. Preprints; 2023 [cited 2023 Jul 5]. Available from: https://www.authorea.com/users/623549/articles/646245-reducing-target-binding-affinity-improves-the-therapeutic-index-of-anti-met-antibody-drug-conjugate-in-tumor-bearing-animals?commit=63c8ca0e12d2bd20e890c99d3daac08bed23b502
   Google Scholar
• Colombo R, Rich JR. The therapeutic window of antibody drug conjugates: a dogma in need of revision. Cancer Cell. 2022;40(11):1255–63. doi:10.1016/j.ccell.2022.09.016.
   PubMed Web of Science ®Google Scholar
• Chemical Computing Group (CCG). | research [Internet]. [cited 2022 Aug 25]; Available from: https://www.chemcomp.com/Research-Citing_MOE.htm
   Google Scholar
• The PyMOL Molecular Graphics System, Version 2.3 Schrödinger, LLC. [Internet]. [cited 2022 Aug 25]; Available from: https://www.schrodinger.com/products/pymol
   Google Scholar
• Kozakov D, Brenke R, Comeau SR, Vajda SP. PIPER: an FFT-based protein docking program with pairwise potentials. Proteins. 2006;65(2):392–406. doi:10.1002/prot.21117.
   PubMed Web of Science ®Google Scholar
• Schrödinger release 2021-3: BioLuminate Schrödinger LLC: New York, 2021 [Internet]. [cited 2022 Aug 25]; Available from: https://www.schrodinger.com/products/bioluminate
   Google Scholar
• Sankar K, Krystek SR Jr, Carl SM, Day T, Maier JKX. AggScore: prediction of aggregation-prone regions in proteins based on the distribution of surface patches. Proteins Struct Funct Bioinf. 2018;86(11):1147–56. doi:10.1002/prot.25594.
   PubMed Web of Science ®Google Scholar
• Ahmed L, Gupta P, Martin KP, Scheer JM, Nixon AE, Kumar S. Intrinsic physicochemical profile of marketed antibody-based biotherapeutics. Proc Natl Acad Sci U S A. 2021;118(37):e2020577118. doi:10.1073/pnas.2020577118.
   PubMed Web of Science ®Google Scholar
• Benatuil L, Perez JM, Belk J, Hsieh C-M. An improved yeast transformation method for the generation of very large human antibody libraries. Protein Eng Des Sel. 2010;23(4):155–59. doi:10.1093/protein/gzq002.
   PubMed Web of Science ®Google Scholar
• Weaver-Feldhaus JM, Lou J, Coleman JR, Siegel RW, Marks JD, Feldhaus MJ. Yeast mating for combinatorial fab library generation and surface display. FEBS Lett. 2004;564(1–2):24–34. doi:10.1016/S0014-5793(04)00309-6.
   PubMed Web of Science ®Google Scholar
• Gaa R, Kumari K, Mayer HM, Yanakieva D, Tsai S-P, Joshi S, Guenther R, Doerner A. An integrated mammalian library approach for optimization and enhanced microfluidics-assisted antibody hit discovery. Artif Cells, Nanomed Biotechnol. 2023;51(1):74–82. doi:10.1080/21691401.2023.2173219.
   PubMed Web of Science ®Google Scholar
• Elter A, Bogen JP, Hinz SC, Fiebig D, Macarrón Palacios A, Grzeschik J, Hock B, Kolmar H. Humanization of Chicken‐Derived scFv using yeast surface display and NGS data mining. Biotechnol J. 2021;16(3):2000231. doi:10.1002/biot.202000231.
   Web of Science ®Google Scholar
• Schröter C, Krah S, Beck J, Könning D, Grzeschik J, Valldorf B, Zielonka S, Kolmar H. Isolation of pH-sensitive antibody fragments by fluorescence-activated cell sorting and yeast surface display. Methods Mol Biol. 2018;1685:311–31.
   PubMedGoogle Scholar
• Becht E, McInnes L, Healy J, Dutertre C-A, Kwok IWH, Ng LG, Ginhoux F, Newell EW. Dimensionality reduction for visualizing single-cell data using UMAP. Nat Biotechnol. 2019;37(1):38–44. doi:10.1038/nbt.4314.
   Web of Science ®Google Scholar
• Yanakieva D, Pekar L, Evers A, Fleischer M, Keller S, Mueller-Pompalla D, Toleikis L, Kolmar H, Zielonka S, Krah S. Beyond bispecificity: controlled fab arm exchange for the generation of antibodies with multiple specificities. MAbs. 2022;14:2018960. doi:10.1080/19420862.2021.2018960.
   PubMed Web of Science ®Google Scholar
• Makowski EK, Wu L, Gupta P, Tessier PM. Discovery-stage identification of drug-like antibodies using emerging experimental and computational methods. MAbs. 2021;13(1):1895540. doi:10.1080/19420862.2021.1895540.
   PubMed Web of Science ®Google Scholar